What is the best strategy after initial treatment with hypomethylating agents for high grade myelodysplatic syndromes, mainly for responders who became transfusion independent?

The hypomethylating agents (HMA’s, 5-azacitidine & decitabine) have important disease modifying properties in addition to relieving cytopenias for patients with high-risk MDS. They decrease the risk of progression to leukemia and improve overall survival. The randomized phase III Aza-001 study dem...